Dermatology Times, September 2024 (Vol. 45. No. 09)

Learn more about the in-depth topics covered in the September 2024 print issue of Dermatology Times.

By offering a wide range of services, dermatologists can provide a holistic approach to skin health.

Zelma Chiesa Fuxench, MD, MSCE, FAAD, and Mona Shahriari, MD, FAAD, discuss the lack of research into psoriasis in skin of color, the absence of diversity in clinical trial populations, and where dermatology as a discipline can go from here.

Peptides are increasingly used in cosmeceuticals for their ability to enhance cellular communication and functionality in antiaging formulations.

Misleading marketing and incomplete scientific data have led to widespread misinformation about botulinum toxin products.

Precision measurements are necessary to improve the current therapeutic armamentarium in pigmentary disorders.

Hurricane flooding results in a surge of mold, mildew, and allergens, which can trigger or exacerbate AD symptoms.

Shanna Miranti, MMS, PA-C, reviews 2 patient cases of pseudo acne fulminans, offering perspectives on treatment and management strategies.

It is important that dermatology providers can easily recognize and treat communicable sports dermatoses, writes Shanna Miranti, MMS, PA-C.

This week’s collection of the latest dermatologic studies includes the prevalence of vulvar dermatoses among ethnically diverse patients, the adaptation of the Mackie melanoma risk stratification tool into a tablet-based patient questionnaire, siblings diagnosed with hereditary sensory and autonomic neuropathy, and more.

Myron Czuczman, MD, of Citius Pharmaceuticals recently shared perspectives on the role and potential of Lymphir in CTCL.

This week’s collection of the latest dermatologic studies includes the impact of isotretinoin treatment on femoral cartilage thickness, cystic fibrosis dermatitis arthritis syndrome, the role of intratumoral therapies for cutaneous melanoma, and fractional pigment toning for treating benign epidermal pigmented lesions.